Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation

doi:10.1186/1471-2407-8-342

BMC Cancer
Volume 8

Viewing options:

Abstract
Full text
PDF (887KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Zhu Z
Chen L
Lu R
Jia J
Liang Y
Xu Q
Zhou C
Wang L
Wang S
Yao Z

on PubMed

Zhu Z
Chen L
Lu R
Jia J
Liang Y
Xu Q
Zhou C
Wang L
Wang S
Yao Z
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research article

Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation

Zhi-feng Zhu^*¹ , Li-juan Chen^*¹ , Rong Lu¹^,2 , Jing Jia¹ , Yu Liang³ , Qiong Xu¹ , Chun-lei Zhou¹ , Li Wang¹ , Song Wang¹ and Zhi Yao¹^,4

¹Department of Immunology, Tianjin Medical University, Tianjin 300070, PR China

²Shenzhen Kangzhe Pharmaceutical Co. Ltd., Shenzhen 518057, PR China

³Department of Histology and Embryology, Tianjin Medical University, Tianjin 300070, PR China

⁴Tianjin Key Laboratory of Cellular and Molecular Immunology, Tianjin Medical University, Tianjin 300070, PR China

author email corresponding author email* Contributed equally

BMC Cancer 2008, 8:342doi:10.1186/1471-2407-8-342


Published:	25 November 2008

Abstract

Background

Tripeptide tyroserleutide (YSL) is a novel small molecule anti-tumor polypeptide that has been shown to inhibit the growth of human liver cancer cells. In this study, we investigated the effects of YSL plus doxorubicin on the growth of human hepatocellular carcinoma BEL-7402 cells that had been transplanted into nude mice.

Methods

Nude mice bearing human hepatocellular carcinoma BEL-7402 tumors were treated with successive intraperitoneal injections of saline; low-, mid-, or high-dose doxorubicin; or low-, mid-, or high-dose doxorubicin plus YSL. Effects on the weight and volume of the tumors were evaluated.

Results

Co-administration of YSL and high-dose doxorubicin (6 mg/kg every other day) prolonged the survival time of tumor-bearing mice as compared to high-dose doxorubicin alone. As well, the anti-tumor effects of mid- and low-dose doxorubicin (2 and 0.7 mg/kg every other day, respectively) were enhanced when supplemented with YSL; the tumor growth inhibition rates for YSL plus doxorubicin were greater than the inhibition rates for the same dosages of doxorubicin alone. The combination of YSL and doxorubicin decreased chemotherapy-associated weight loss, leukocyte depression, and heart, liver, and kidney damage as compared to doxorubicin alone.

Conclusion

The combination of YSL plus doxorubicin enhances the anti-tumor effect and reduces the side effects associated with doxorubicin chemotherapy.